Tags

Type your tag names separated by a space and hit enter

High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
J Neural Transm (Vienna). 2020 03; 127(3):311-322.JN

Abstract

Differential diagnosis between Parkinson's disease (PD) Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), namely spectrum of Lewy bodies disorders (LBDs), may be challenging, and their common underlying pathophysiology is debated. Our aim was to examine relationships among neurodegenerative biomarkers [alpha-synuclein (α-Syn), Alzheimer's Disease (AD)-related (beta-amyloid Aβ42, tau [total τΤ and phosphorylated τp-181]), dopaminergic imaging (DATSCAN-SPECT)] and spectrum of LBD. This is a cross-sectional prospective study in 30 PD, 18 PDD, 29 DLB patients and 30 healthy controls. We compared α-Syn in CSF, plasma and serum and CSF Aβ42, τΤ and τp-181 across these groups. Correlations between such biomarkers and motor, cognitive/neuropsychiatric tests, and striatal asymmetry indexes were examined. CSF α-Syn was higher in DLB versus PD/PDD/controls, and lower in PD and PDD patients compared to controls (all p < 0.001). Serum α-Syn levels were higher in all patient groups compared to controls. After excluding those DLB patients with CSF AD profile, plasma and serum Syn levels were higher in the LBD group as a whole compared to controls. The combination of CSF α-Syn, serum α-Syn and Aβ42 for comparison between PD and DLB [AUC = 0.96 (95% CI 0.90-1.00)] was significantly better when compared to serum α-Syn alone (p < 0.001). Correlation analyses of biomarkers with cognitive/neuropsychiatric scales revealed some associations, but no consistent, cohesive picture. Peripheral biomarkers such as serum α-Syn, and CSF α-Syn and Aβ42 may contribute as potential biomarkers to separate LBDs from controls and to differentiate DLB from the other LBDs with high sensitivity and specificity among study groups.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Bougea A
1st Department of Neurology, Memory and Movement Disorder Clinic, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Vassilisis Sophias Avenue 72-74, 11528, Athens, Greece. annita139@yahoo.gr. Department of Neuroscience, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. annita139@yahoo.gr.
Stefanis L
1st Department of Neurology, Memory and Movement Disorder Clinic, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Vassilisis Sophias Avenue 72-74, 11528, Athens, Greece. Department of Neuroscience, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Emmanouilidou E
Department of Neuroscience, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Vekrelis K
Department of Neuroscience, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Kapaki E
1st Department of Neurology, Memory and Movement Disorder Clinic, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Vassilisis Sophias Avenue 72-74, 11528, Athens, Greece.

MeSH

AgedAmyloid beta-PeptidesBiomarkersDementiaDiagnosis, DifferentialFemaleHumansLewy Body DiseaseMaleMiddle AgedNeuropsychological TestsParkinson DiseasePeptide FragmentsTomography, Emission-Computed, Single-Photonalpha-Synucleintau Proteins

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31912280

Citation

Bougea, Anastasia, et al. "High Discriminatory Ability of Peripheral and CFSF Biomarkers in Lewy Body Diseases." Journal of Neural Transmission (Vienna, Austria : 1996), vol. 127, no. 3, 2020, pp. 311-322.
Bougea A, Stefanis L, Emmanouilidou E, et al. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. J Neural Transm (Vienna). 2020;127(3):311-322.
Bougea, A., Stefanis, L., Emmanouilidou, E., Vekrelis, K., & Kapaki, E. (2020). High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. Journal of Neural Transmission (Vienna, Austria : 1996), 127(3), 311-322. https://doi.org/10.1007/s00702-019-02137-2
Bougea A, et al. High Discriminatory Ability of Peripheral and CFSF Biomarkers in Lewy Body Diseases. J Neural Transm (Vienna). 2020;127(3):311-322. PubMed PMID: 31912280.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. AU - Bougea,Anastasia, AU - Stefanis,Leonidas, AU - Emmanouilidou,Evangelia, AU - Vekrelis,Kostas, AU - Kapaki,Elisabeth, Y1 - 2020/01/07/ PY - 2019/10/19/received PY - 2019/12/27/accepted PY - 2020/1/9/pubmed PY - 2021/3/27/medline PY - 2020/1/9/entrez KW - Alpha‐synuclein (α-Syn) KW - Biomarkers KW - Lewy bodies disorders (LBDs) KW - Single photon emission computerized tomography of the dopamine transporter (DATSCAN–SPECT) SP - 311 EP - 322 JF - Journal of neural transmission (Vienna, Austria : 1996) JO - J Neural Transm (Vienna) VL - 127 IS - 3 N2 - Differential diagnosis between Parkinson's disease (PD) Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), namely spectrum of Lewy bodies disorders (LBDs), may be challenging, and their common underlying pathophysiology is debated. Our aim was to examine relationships among neurodegenerative biomarkers [alpha-synuclein (α-Syn), Alzheimer's Disease (AD)-related (beta-amyloid Aβ42, tau [total τΤ and phosphorylated τp-181]), dopaminergic imaging (DATSCAN-SPECT)] and spectrum of LBD. This is a cross-sectional prospective study in 30 PD, 18 PDD, 29 DLB patients and 30 healthy controls. We compared α-Syn in CSF, plasma and serum and CSF Aβ42, τΤ and τp-181 across these groups. Correlations between such biomarkers and motor, cognitive/neuropsychiatric tests, and striatal asymmetry indexes were examined. CSF α-Syn was higher in DLB versus PD/PDD/controls, and lower in PD and PDD patients compared to controls (all p < 0.001). Serum α-Syn levels were higher in all patient groups compared to controls. After excluding those DLB patients with CSF AD profile, plasma and serum Syn levels were higher in the LBD group as a whole compared to controls. The combination of CSF α-Syn, serum α-Syn and Aβ42 for comparison between PD and DLB [AUC = 0.96 (95% CI 0.90-1.00)] was significantly better when compared to serum α-Syn alone (p < 0.001). Correlation analyses of biomarkers with cognitive/neuropsychiatric scales revealed some associations, but no consistent, cohesive picture. Peripheral biomarkers such as serum α-Syn, and CSF α-Syn and Aβ42 may contribute as potential biomarkers to separate LBDs from controls and to differentiate DLB from the other LBDs with high sensitivity and specificity among study groups. SN - 1435-1463 UR - https://www.unboundmedicine.com/medline/citation/31912280/High_discriminatory_ability_of_peripheral_and_CFSF_biomarkers_in_Lewy_body_diseases_ DB - PRIME DP - Unbound Medicine ER -